Viridian Therapeutics, Inc. (VRDN) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $16.25: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 9.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 1.39; Below-average business quality.
Viridian Therapeutics is a clinical-stage biopharmaceutical company developing veligrotug (IV IGF-1R, BLA under Priority Review with PDUFA June 30, 2026) and elegrobart (SC IGF-1R, Phase 3 REVEAL-1/2 results expected Q1/Q2 2026) for thyroid eye disease, plus FcRn inhibitors... Read more
Sell if holding. Engine safety override at $16.25: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 9.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 1.39; Below-average business quality. Chart setup: RSI 43 mid-range, Bollinger mid-band. Score 5.3/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
About Viridian Therapeutics, Inc.
About Viridian Therapeutics, Inc.
Viridian Therapeutics has no approved products, making its Phase 3 veligrotug program the sole near-term value inflection — the FDA granted Priority Review on a veligrotug BLA accepted in December 2025, with a PDUFA target action date of June 30, 2026, and the company additionally submitted an MAA to the EMA in January 2026. Cash and marketable securities stood at $874.7 million at December 31, 2025, against a net loss of $342.6 million for the year and an accumulated deficit of $1,338.5 million.
Viridian generates no revenue from product sales and has financed operations through equity, debt, and collaboration agreements. The company holds worldwide commercialization rights to veligrotug and elegrobart, excluding Japan and the greater China area, under arrangements that include royalty and milestone obligations. Veligrotug competes directly with Tepezza (teprotumumab), marketed by Amgen, which posted approximately $1.9 billion in 2025 net sales at an estimated list price of $525,000 per course; veligrotug's five-dose IV regimen features fewer infusions versus teprotumumab's eight-dose regimen. Elegrobart, a subcutaneous IGF-1R antibody with a 40–50-day half-life, is in Phase 3 pivotal studies REVEAL-1 and REVEAL-2, which completed enrollment in September 2025, with topline data expected in Q1 and Q2 2026, respectively. A TSHR inhibitor program IND is planned for Q4 2026. Manufacturing relies on CDMOs and external suppliers subject to FDA cGMP inspection rights.
Show full overview
The regulatory pathway for veligrotug rests on the THRIVE and THRIVE-2 Phase 3 trials plus a 300-patient safety database; however, the 10-K warns the FDA may require additional patients or steps beyond what the company has planned. Elegrobart's eventual BLA also depends on demonstrating bioequivalence between the vial formulation used in REVEAL-1/REVEAL-2 and the planned autoinjector — a risk the 10-K flags as potentially delaying or denying approval if bioequivalence is not shown. In May 2026, Viridian disclosed via Form 8-K the voluntary termination of the Hercules Capital term loan following a $55.1 million prepayment, removing financial covenants that had constrained capital deployment ahead of a potential commercial launch.
See also: Healthcare · Biotechnology
From Viridian Therapeutics, Inc.'s most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated 2026-06-15Recent Developments — Viridian Therapeutics, Inc.
Material events (past 30 days)
- 8K May 28, 2026 MEDIUM Item 1.02: On May 27, 2026, Viridian Therapeutics voluntarily prepaid ~$55.1 million to Hercules Capital, fully terminating the April 2022 Loan and Security Agreement ($50M drawn of $300M max, floating rate capped at 9.45%). All obligations discharged in full.
Latest news
- NEWS Viridian Therapeutics Strikes Commercial Manufacturing Services Agreement With WuXi Biologics To Produce, Supply Veligro — benzinga May 26, 2026 positive
- NEWS Evercore ISI Group Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $26 — benzinga May 15, 2026 positive
- NEWS Reported Earlier, Viridian Therapeutics Prices Upsized $350M Concurrent Offerings Of $225M 1.75% Convertible Notes Due 2 — benzinga May 7, 2026 positive
- NEWS RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $34 — benzinga May 6, 2026 positive
- NEWS 12 Health Care Stocks Moving In Tuesday's Intraday Session — benzinga May 5, 2026 neutral
Generated 2026-06-17T08:21:49Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $16.25: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 9.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 1.39; Below-average business quality. Chart setup: RSI 43 mid-range, Bollinger mid-band. Prior stop was $15.12. Score 5.3/10, moderate confidence.
Take-profit target: $30.54 (+87.9% upside). Prior stop was $15.12. Stop-loss: $15.12.
Quality below floor (1.6 < 4.0).
Viridian Therapeutics, Inc. trades at a P/E of N/A (forward -6.5). TrendMatrix value score: 5.4/10. Verdict: Sell.
23 analysts cover VRDN with a consensus score of 4.3/5. Average price target: $34.
What does Viridian Therapeutics, Inc. do?Viridian Therapeutics is a clinical-stage biopharmaceutical company developing veligrotug (IV IGF-1R, BLA under...
Viridian Therapeutics is a clinical-stage biopharmaceutical company developing veligrotug (IV IGF-1R, BLA under Priority Review with PDUFA June 30, 2026) and elegrobart (SC IGF-1R, Phase 3 REVEAL-1/2 results expected Q1/Q2 2026) for thyroid eye disease, plus FcRn inhibitors VRDN-006 and VRDN-008 for autoimmune disorders. No products approved; $874.7M cash as of December 31, 2025.